Taken together, IM-induced activation of FGF-signaling pathway in GISTs is in agreement with a paradigm indicating that FGFRs and their ligand, FGF-2, could work as a surrogate signaling pathway under the inhibition of RTK-signaling and mediate tumor resistance to RTK inhibitors (RTKi) and chemotherapeutic agents as well. The gene discussed is FGF2; the disease is neoplasm.